Patients who develop immunotherapy-related colitis tend to have better outcomes, so it is important to get them back on treatment as soon as possible.
Immunotherapy-related colitis is a "hot topic" in the world of oncology, according to Yinghong Wang, MD, PhD, MS, gastroenterologist, Department of Gastroenterology Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center. It is important that the healthcare team treat patients with colitis quickly and effectively, so that they can get back on treatment as soon as possible, and stay on treatment as well.
Transcription:
This is a hot topic because we see so many patients who have colitis from checkpoint inhibitors and we want to improve our quality of service to get the patients’ symptoms under control as soon as possible and as effectively as possible. Patients who develop GI-related toxicity tend to have a better cancer outcome. Therefore, our goal is to put them back on the immunotherapy as fast as possible and keep them on as long as possible.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
Side Effect Education Critical for Patients With Cervical Cancer Treated With Pembrolizumab
January 22nd 2024With pembrolizumab plus chemoradiotherapy now approved by the FDA for patients with advanced cervical cancer, one expert explained the importance of “making sure that patients know what to look for and what to report.”
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
Side Effect Education Critical for Patients With Cervical Cancer Treated With Pembrolizumab
January 22nd 2024With pembrolizumab plus chemoradiotherapy now approved by the FDA for patients with advanced cervical cancer, one expert explained the importance of “making sure that patients know what to look for and what to report.”
Frontline Durvalumab Regimen Improves PFS, Responses in Advanced Endometrial Cancer
Pembrolizumab Plus Chemo Provides Overall Survival Benefit in Endometrial Cancer
Dostarlimab Plus Chemo Demonstrates 31% OS Improvement in Advanced Endometrial Cancer
Olaparib Plus Cediranib May Not Provide Survival Benefit in Platinum-Resistant or Refractory Ovarian Cancer
2 Commerce Drive
Cranbury, NJ 08512